Pinnacle Associates Reduces Johnson & Johnson Stake

Institutional investor cuts position in healthcare giant by 17.2% in Q3

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Pinnacle Associates Ltd., an institutional investor, reduced its position in Johnson & Johnson (NYSE: JNJ) by 17.2% in the third quarter, according to a recent SEC filing. The firm now owns 1,659,970 shares of the company's stock, valued at approximately $307.8 million.

Why it matters

Johnson & Johnson is a bellwether stock in the healthcare sector, and changes to major institutional holdings can signal broader market trends or shifts in investor sentiment. Pinnacle Associates' decision to trim its JNJ stake may reflect broader concerns about the company's outlook or the overall market environment.

The details

According to the 13F filing, Pinnacle Associates sold 345,156 shares of Johnson & Johnson stock during the third quarter. The firm now owns approximately 0.07% of the company's outstanding shares. Johnson & Johnson accounts for around 4.1% of Pinnacle Associates' total investment portfolio, making it the firm's second-largest holding.

  • Pinnacle Associates reduced its JNJ stake in the third quarter of 2026.

The players

Pinnacle Associates Ltd.

An institutional investment firm that manages a diversified portfolio of stocks, bonds, and other assets.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

Pinnacle Associates' decision to trim its Johnson & Johnson position may signal broader concerns about the healthcare sector or the overall market environment. Investors will be watching to see if other major institutional holders follow suit or if JNJ can maintain its status as a defensive blue-chip stock.